MAM
Sandeep Goyal’s Mogae & Zeotap ink JV for programmatic advertising on mobile
MUMBAI: Sandeep Goyal’s Mogae Media has signed an MoU for a joint venture (JV) with Germany’s Zeotap for programmatic advertising on smartphones.
The JV will bring to India the world’s most trusted platform for enriched, profiled and targeted mobile advertising. The new company will see an equal participation by both Mogae and Zeotap. The final financial structures are currently being worked upon.
“Programmatic buying involves a paradigm shift in the approach to digital advertising from the entire ecosystem – brands, agencies, publishers, not forgetting the availability and capability of technology platforms (demand side platform, supply side platform, data management platform) to execute the true potential of programmatic. Programmatic is an ideal technique to move marketing from a fragmented campaign-by-campaign paradigm to an always-on paradigm covering the entire customer lifecycle. With Zeotap, we wish to do just that,” said Mogae Media chairman Sandeep Goyal.
“The new investment will be employed towards Zeotap’s international expansion as well as to substantially grow our global technology centre in Bangalore,” added Zeotap CEO Daniel Heer.
Zeotap co-founder and chief product officer (CPO) Projjol Banerjea said, “Zeotap’s platform makes some of the most comprehensive ad targeting capabilities available to the mobile advertising market. We work with publishers and supply-side platforms to optimize yield as well as advertisers and demand-side players to make ad buying more efficient. The company operates in Europe and Asia.”
The Mogae-Zeotap JV platform will be live by September. A larger rollout is planned over the next 6-19 months.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
